The neuronal microtubule-associated protein tau serves a critical role in regulating axonal microtubule dynamics to support neuronal and synaptic functions. Furthermore, it contributes to glutamatergic regulation and synaptic plasticity. Emerging evidence also suggests that tau serves as a signaling scaffold. Tau function and subcellular localization are tightly regulated, in part, by the orchestrated interplay between phosphorylation and dephosphorylation events. Significantly, protein phosphatase type 2A (PP2A), encompassing the regulatory PPP2R2A (or Ba) subunit, is a major brain heterotrimeric enzyme and the primary tau Ser/Thr phosphatase in vivo. Herein, we closely examine how the intimate and compartmentalized interactions between PP2A and tau regulate tau phosphorylation and function, and play an essential role in neuronal homeostasis. We also review evidence supporting a strong link between deregulation of tau-PP2A functional interactions and the molecular underpinnings of various neurodegenerative diseases collectively called tauopathies. Lastly, we discuss the opportunities and associated challenges in more specifically targeting PP2A-tau interactions for drug development for tauopathies.
The neuronal microtubule-associated protein tau serves a critical role in regulating axonal microtubule dynamics to support neuronal and synaptic functions. Furthermore, it contributes to glutamatergic regulation and synaptic plasticity. Emerging evidence also suggests that tau serves as a signaling scaffold. Tau function and subcellular localization are tightly regulated, in part, by the orchestrated interplay between phosphorylation and dephosphorylation events. Significantly, protein phosphatase type 2A (PP2A), encompassing the regulatory PPP2R2A (or Ba) subunit, is a major brain heterotrimeric enzyme and the primary tau Ser/Thr phosphatase in vivo. Herein, we closely examine how the intimate and compartmentalized interactions between PP2A and tau regulate tau phosphorylation and function, and play an essential role in neuronal homeostasis. We also review evidence supporting a strong link between deregulation of tau-PP2A functional interactions and the molecular underpinnings of various neurodegenerative diseases collectively called tauopathies. Lastly, we discuss the opportunities and associated challenges in more specifically targeting PP2A-tau interactions for drug development for tauopathies.
Keywords: dephosphorylation; PP2A; protein interactions; tau; tauopathies Tau proteins are major brain microtubule-associated proteins (Reviewed in Ref. [1] ). There are multiple tau isoforms (See Fig. 1 ) generated via alternative splicing of the encoding MAPT gene. All six isoforms are expressed in the adult brain with considerable regional variation, but tau mRNA and protein levels are twofold enriched in the neocortex relative to white matter and cerebellum [2] . It is well established that tau functions to maintain microtubule stability, which contributes to its role in microtubule-dependent transport of cellular cargo. In addition to supporting synapse function through this role, tau also contributes to postsynaptic signaling scaffolds and synaptic plasticity. In particular, hippocampal long-term depression (LTD) is dependent on the presence of tau [3] . Tau proteins have attracted significant attention due to their central pathological role in a variety of neurodegenerative diseases designed as 'tauopathies', wherein characteristic aggregates of 'hyperphosphorylated' tau proteins deposit in affected brain regions (Reviewed in Ref.
[1]). Hence, historically, tau phosphorylation has been principally studied in the general neuropathological context of its excessive or aberrant phosphorylation, which was considered as a prelude to its toxic aggregation in the dementia brain. In contrast, comparatively little progress has been made in understanding the physiological relevance of site-specific tau phosphorylation and dephosphorylation events. How such processes precisely affect the normal function of tau in neuronal homeostasis-beyond its canonical role in regulating microtubule dynamics-remain, for the most part, to be clarified.
The phosphorylation status of tau is tightly controlled by a delicate balance between protein kinases' and phosphatases' activities. Among the many brain protein kinases that regulate tau (Reviewed in Ref.
[4]), by far, glycogen synthase kinase 3b (GSK 3b) is the major Ser/Thr tau kinase. It contributes to the pathology of several neurodegenerative diseases [5] . Importantly, GSK3b phosphorylates the Ser-396 residue of tau, which is critical for LTD [3, 6] . Of particular relevance, the phosphatase battlefront is largely led by a distinct pool of protein phosphatase 2A (PP2A) enzymes that are responsible for the bulk of neuronal tau dephosphorylation [7, 8] . PP2A is a highly conserved, essential, and omnipresent family of protein Serine (Ser) and Threonine (Thr) phosphatases that play a central role in signal transduction pathways and cell homeostasis [9] .
Here, we more specifically review how PP2A enzymes directly or indirectly regulate tau phosphorylation state, thereby impacting tau function under various physiological and pathological conditions. In contrast to the reductionist view that PP2A only regulates tau via its role as a potent Ser/Thr tau phosphatase, recent studies emphasize that PP2A also serves an important function in controlling tau subcellular targeting and scaffolding function. Indeed, we discuss how direct protein-protein interactions between PP2A and tau can also modulate tau function, and how pathological disruption of such interactions could contribute to tauopathies. Based on the critical importance of PP2A in tau regulation, and its known dysfunction in neurodegenerative diseases Fig. 1 . Mapping of the interaction of PP2A/Ba with human brain tau isoforms. Major domains in the tau protein include the N-terminal projection domain, which projects away from microtubules, and the microtubule-binding domain, comprised of a proline-rich region, repeat (R) domains and a flanking region at the carboxy-terminal. The six human brain tau isoforms shown are generated through alternative splicing, yielding tau species with either 0, 1, or 2 amino-terminal inserts (0N, 1N, or 2N), and either three (3R) or four (4R) carboxy-terminal repeat domains. The PP2A/Ba enzyme interacts with all tau isoforms via a domain encompassing the MT-binding repeats and upstream proline-rich region, which harbors the conserved RTPPKSP motif that is critical for PP2A binding. As shown (blue text), PP2A dephosphorylates tau at various serine (Ser) and threonine (Thr) sites in vitro (all sites listed) and in vivo (sites in bold text). Frontotemporal dementia-associated tau mutations (red), harbored in the PP2A-binding sequence inhibit the interaction of PP2A with tau.
(Reviewed in Ref.
[10]), we will also debate whether targeting PP2A could be a viable option to develop therapeutic strategies for tauopathies. 
PP2A isoforms indirectly control tau phosphorylation via their action on tau kinases
Besides PP2A/Ba, other PP2A isoforms have been found to regulate phospho-tau homeostasis via indirect mechanisms, by modulating upstream tau protein kinases [18, 21] . For instance, PP2A/Ba holoenzymes can regulate the activities of many Ser/Thr tau kinases, such as ERK [22] . In addition, B56d subunit-containing PP2A isoforms influence tau phosphorylation through dephosphorylation and subsequent activation of GSK3b [23] ; knockout of B56d results in progressive tau phosphorylation at pathological sites implicated in tauopathies [21] . In support of the critical role of PP2A in the regulation of tau phosphorylation state, PP2A inhibition can also overcome the inhibition of key tau kinases (cdk5 and GSK3b), and promote tau hyperphosphorylation in the hippocampus of starved mouse [24] .
PP2A-tau interactions play a key role in tau regulation
Mapping of the tau interaction domain in PP2A
Without the Ba subunit, the PP2A AC core enzyme only weakly binds to tau and partially dephosphorylates tau [7] , further cementing the role of Ba in promoting PP2A substrate selectivity. Studies using tau mutants have shown that the microtubule binding domain and the upstream proline-rich region in tau are important for PP2A binding [16] . Further structural studies have described a highly acidic groove harbored in the top face of the seven-bladed b-propeller of Ba; this allows the Ba subunit to bind to two nonoverlapping peptide fragments (residues 197-259 and 265-328 of the 0N4R tau isoform shown in Fig. 1 ) enriched in positively charged amino acids, which fall within the MT-binding repeats of tau [15] . The presence of more than one PP2A/Ba-binding site in tau strategically maximizes the efficiency of PP2A-dependent tau dephosphorylation, by enhancing the presentation of the multiple and dispersed Ser/Thr phosphorylated residues in tau to PP2A catalytic subunit [15] .
Disruption of PP2A-tau interactions by PP2A deregulation
Of particular relevance to PP2A-dependent tau dephosphorylation, several studies indicate that the assembly and stabilization of PP2A/Ba holoenzymes are promoted by methylation of PP2A catalytic C subunit at Leu309 by leucine carboxyl methyltransferase 1 (LCMT1). Decreased PP2A methylation levels can lead to a loss of PP2A/Ba and concomitant changes in endogenous PP2A subunit composition that affect PP2A substrate specificity and targeting (Reviewed in Ref.
[10]). Accordingly, downregulation of PP2A methylation is associated with the disruption of PP2A-tau protein-protein interactions, thereby precluding PP2A-mediated tau dephosphorylation [25, 26] . Significantly, decreased LCMT1 and methylated PP2A levels [27] correlate with reduced PP2A/Ba amounts and the severity of phospho-tau pathology in Alzheimer disease (AD)-affected brain regions [28] . Thus, by affecting intracellular pools of PP2A/Ba, changes in PP2A methylation, for instance in response to disturbances in one-carbon metabolism, have the potential to offset the delicate equilibrium between tau kinases' and phosphatases' activities. Such alterations may render tau more susceptible to phosphorylation events and even increase its interaction with certain kinases (See below).
Protein phosphatase 2A is also targeted by numerous endogenous regulators such as SET (or I 2 PP2A), a potent inhibitor that binds to PP2A C subunit resulting in inhibition of its tau phosphatase activity [29] . SET is primarily nuclear, but can translocate to the cytoplasm under certain conditions. Cytoplasmic retention of SET is associated with reduced PP2A activity and methylation, and enhanced tau phosphorylation at Ser202 [30] . The cytoplasmic translocation of SET has been observed in susceptible neurons of AD [31] and Down syndrome [32] patients, and could represent one of the multiple mechanisms for the abnormally elevated levels of phosphorylated tau accompanying these disorders.
Regulation of PP2A-tau interactions by tau phosphorylation
Although deregulation of PP2A/Ba can affect its ability to interact with tau and consequently tau (de)phosphorylation state, phosphorylation of tau at specific sites has also the potential to affect its ability to associate with the phosphatase. Indeed, AD-like pseudophosphorylation of several tau sites in the N-terminal prolinerich region of tau inhibits the association of tau with PP2A [33] . More specifically, phosphorylation of Thr231 in the proline-rich 230 RTPPKSP 236 motif of tau significantly decreases binding of tau to PP2A in vitro [34] , which provides a plausible explanation for the poor dephosphorylation of pThr231-Tau by PP2A/Ba [35] . Of clinical significance, phosphorylation of tau at Thr231 is found in early AD and prevents further dephosphorylation of pathological pS202/pThr205 tau sites by PP2A/Ba [35] .
Disruption of PP2A-tau interactions by tau mutations
Many mutations of the MAPT gene have been described in familial non-AD tauopathies. They cause dementia by various mechanisms, with changes in alternative splicing, phosphorylation state, interaction with tubulin and self-assembly into filaments being the most significant contributing factors to the underlying tau pathology [36] . Notably, frontotemporal dementia with parkinsonism-17 (FTDP-17)-associated missense mutations G272V, DK280, P301L, P301S, S305N, V337M, G389R, and R406W are harbored within the PP2A/Ba interacting domain of tau and inhibit the binding of tau to PP2A/Ba by~20-70% [37] (Fig. 1) . As discussed earlier, the reduced binding of mutated tau to PP2A could favor the accumulation of phosphorylated tau, by interfering with tau dephosphorylation processes.
Influence of other proteins on PP2A-tau interactions
Like tau, pools of PP2A/Ba are also anchored to the microtubule wall, but both PP2A and tau bind at distinct sites on polymerized tubulin [16] . Interestingly, the association of PP2A with microtubules could act as a regulatory mechanism to sequester the phosphatase and circumvent the untimely dephosphorylation of microtubule-associated proteins, considering that this cytoskeletal anchoring induces an inhibitory effect on the tau phosphatase activity of PP2A [16] . PP2A/Ba is also influenced by microtubule dynamics since tubulin assembly decreases PP2A/Ba activity in vitro [16] . Together, these findings infer that tau and PP2A only interact when they both dissociate from the microtubule cytoskeleton (Reviewed in Ref.
[9]).
Other cytoskeletal components such as neurofilaments may also indirectly interfere with PP2A-tau interactions. It is well established that the neurofilament architecture that supports axonal caliber and function is regulated by PP2A activity (Reviewed in Ref.
[9]). Since Ba-containing PP2A complexes associate quite strongly with neurofilaments [38] , it is possible that this cytoskeletal interaction also serves to isolate PP2A/Ba pools from tau, so that neurofilament dynamics could also indirectly influence PP2A's tau phosphatase activity.
Of importance to tauopathies, certain protein kinases could also affect PP2A/Ba activity toward phosphorylated tau. For instance, Fyn, a Src family nonreceptor tyrosine kinase, binds in vitro to the 230 RTPPKSP 236 motif of tau, thereby inhibiting the interaction of PP2A with tau through competitive binding [34] . It is noteworthy that increased Fyn-tau and decreased PP2A-tau interactions have been observed with disease-associated tau phosphorylation in the proline-rich region, as well as with frontotemporal dementia-associated tau mutations (Reviewed in Ref. [9] ). Future studies will likely uncover additional modulators of PP2A-tau interactions.
PP2A: A chief conductor of tau subcellular distribution

Phosphorylation of tau orchestrates its subcellular targeting
Physiologically, tau is enriched in axons of mature neurons and serves various crucial functions not confined to the axoplasm. A key finding that has dramatically enhanced our understanding of tau is that pseudophosphorylation of selective Ser/Thr residues leads to its detachment from microtubules and subsequent redistribution to somatodendritic compartments, in particular, dendritic spines [39] . When deregulated, this mechanism could result in synaptic impairment [40] . Furthermore, deletion of the microtubule-binding repeat domain or P301L mutations in tau, both of which affect PP2A binding, target tau to dendritic spines [39] .
Besides its primary residence in axons, tau is also present in the nucleus, predominantly in a hypophosphorylated state [41] . It is likely that nuclear PP2A/Ba pools present in neurons [38] could contribute to maintain nuclear tau in this dephosphorylated state, which underlies its DNA-protective functions [42, 43] (Fig. 2) .
Tau proteins are also targeted to the plasma membrane (Fig. 2) mostly in a dephosphorylated state [44] . Notably, downregulation of PP2A methylation leads to a loss of membrane-associated tau, and concomitant cytoplasmic accumulation of phosphorylated tau [45] . These findings suggest that tau phosphorylation state, at least in part, regulates its association with plasma membrane microdomains enriched with PP2A/Ba [45] and other key signaling molecules. Tau likely carries out a major scaffolding function in the assembly of these signaling complexes.
Physiological significance of PP2A-dependent tau regulation
Microtubules decorated with tau have altered dynamics
The most recognized function of tau is its ability to regulate microtubule dynamics (Reviewed in Ref.
[9]). Tau binding to microtubules is regulated by site-specific phosphorylation, and is therefore overly dependent on PP2A/Ba (Fig. 2) . Indeed, specific PP2A inhibition disrupts microtubule binding and stability, and is invariably associated with increased tau phosphorylation [7] .
An important role of tau in axonal transport and synaptic plasticity
The distribution of tau along the axonal length is critical for the translocation of motor proteins, and thus, the flux of organelles and other cellular cargo. In healthy axons, tau distribution is nonuniform owing to a proximal to distal (with respect to the axon) increase in the concentration gradient [46] . Importantly, this enhances organelle flux and maximizes fast axonal transport toward the synapses [47, 48] . The motor proteins dynein and kinesin frequently encounter tau patches along their path, which hinder their motility, leading to the reversal of direction or detachment, respectively [49] . Kinesin efficiently binds tau in the cell body wherein tau concentration is minimal, initiating anterograde transport; ultimately, the motor protein is released at the distal end of the axon characterized by higher tau concentrations [49] . Relative to kinesin, dynein can bind microtubules distally because of its lower sensitivity to tau, and initiates dynein-driven retrograde transport. It is likely that this phenomenon governed by the distinct occupancy of tau along axons can be fine-tuned by modulating phosphorylation and dephosphorylation within tau's microtubule-binding domain.
A signaling function of tau
Beyond its traditional role confined to axons, there is an increasing interest in noncanonical functions of tau such as facilitating glutamate signaling (Fig. 3 ). It appears that under normal physiological conditions, tau strategically traffics Fyn to postsynaptic densities (PSDs). There, tau serves a critical role in synaptic plasticity by stabilizing N-Methyl-D-aspartate receptors (NMDARs) by promoting their complex formation with the scaffolding protein, postsynaptic density protein 95 (PSD-95) [50] . From a neuropathological context, this role of tau boosts excitotoxicity and increases amyloid-b-mediated neurotoxicity during AD pathogenesis [51] . Upon NMDAR activation, tau dissociates from GluN2B subunit-containing NMDAR-PSD-95 scaffolds leading to increased tau phosphorylation at various Ser/Thr sites, while weakening its interaction with PSD-95 [52] . Tau leaves the NMDAR-PSD-95 complex with increased affinity for Fyn [52] . In this context, tau phosphorylation could In the axon where tau is enriched, spatial dephosphorylation of tau is influenced by the regulated binding of PP2A/Ba to neuronal microtubules. Tau binding to microtubules decreases their intrinsic dynamic instability and significantly influences bidirectional axonal transport. PP2A/Ba enzymes are sequestered in an inactive state on microtubules and released upon microtubule depolymerization. The direct association of PP2A/Ba with tau in the cytosol induces tau dephosphorylation. Tau may also exert other compartmentalized functions. For instance, nuclear pools of hypophosphorylated tau protect DNA from damage induced by thermal and oxidative stress. The proline-rich and R2 motifs anchor tau to DNA; this interaction is facilitated by tau dephosphorylation, which could be promoted by nuclear PP2A/Ba enzymes. Furthermore, PP2A methylation is required for the targeting of PP2A/Ba holoenzymes and tau to the plasma membrane [45] , wherein tau could serve as a scaffold for signaling molecules. The tau-membrane interaction is inhibited by site-specific phosphorylation and involves tau's N-terminal projection domain [44] .
prevent excitotoxicity through destabilizing these multifaceted excitatory complexes by abrogating their interaction with Fyn. Interestingly, overexpressing a phosphomimetic tau species significantly enhances NMDAR currents and facilitates hippocampal LTD [52] . In support of this finding, a recent study in hippocampal slices has demonstrated that tau phosphorylation at Ser396 is required for LTD [6] . Hence, the phosphorylation of tau in response to NMDAR activation could explain why a small pool of phosphorylated tau is found in dendrites [52] .
To prevent excessive, neurotoxic phosphorylation, the phosphorylated state of dendritic tau is likely controlled by a pool of PP2A, which is also found in PSDs and synaptic plasma membrane fractions. There, PP2A functionally associates with NR3 subunit-containing NMDAR complexes [53] . PP2A dissociates in a catalytically inactive state from these particular complexes following NMDAR activation [54] (Fig. 3) . Thus, delineating the regulation of tau and PP2A in postsynaptic signaling events is essential for understanding the mechanisms leading to the pathological accumulation of phosphorylated tau species, which in turn enhances NMDAR-dependent Ca 2+ influx and promotes glutamate excitotoxicity [51] .
Tau has also been reported to negatively regulate ERK signaling, an important cascade for neuronal survival; depletion of tau induced ERK activation in mouse cortical neurons following extrasynaptic NMDAR stimulation [55] . Tau overexpression also primes Src for activation and influences Src-mediated actin remodeling in growth factor-stimulated cells [56] .
A role for tau in genomic DNA protection and repair Interestingly, tau also functions in the nucleus to protect DNA against oxidative stress and denaturation by hyperthermia [42, 43] (Fig. 2) . Foci of phosphorylated histone H2AX, a double-strand DNA break marker, have been found in tau-knockout mice during hyperthermic conditions [57] . Both genomic DNA and RNA integrity are altered under hyperthermic conditions in tau depleted hippocampal neurons [57] . It has been observed that nuclear tau is predominantly hypophosphorylated [41] , which may promote its binding to the DNA backbone [42, [58] [59] [60] . Like tau, PP2A functions in the nucleus to mediate DNA repair, and suppression of specific B subunits, including Ba, sensitizes cells to DNA damage-inducing agent [61] [62] [63] [64] . PP2A/ B56e enzymes function in the repair process of doublestrand breaks by dephosphorylating phosphorylated histone H2AX [61] . It is thus tempting to speculate that alterations in tau phosphorylation state could Fig. 3 . An important role for tau in synaptic plasticity. Hetero-multimeric NMDA receptors (NMDARs) play a key role in synaptic plasticity, and their overactivation has been linked to excitotoxicity in Alzheimer disease. A small pool of endogenously phosphorylated tau is present in dendrites and synapses. In this model, tau interacts with a multifaceted complex including NR2-containing NMDAR, Fyn and PSD-95; this interaction is governed by the phosphorylation state of tau and tau-Fyn binding. NMDAR activation increases tau phosphorylation at Ser/Thr sites resulting in dissociation of tau and Fyn from the postsynaptic scaffold; this facilitates long-term depression (LTD). Interestingly, PP2A/ Ba functionally interacts with the NR3 subunit-containing NMDAR complexes; it dephosphorylates Ser-897 on the NR1 subunit, which is known to regulate NMDAR activity. Upon NMDAR activation, PP2A dissociates in an inactive state. PP2A has been shown to be required for LTD. PP2A also competes with Fyn for binding to tau, and could therefore participate in modulating this glutamatergic cascade, by regulating Fyn-tau interactions and/or inducing tau dephosphorylation at Ser/Thr sites. Deregulation of normal tau-Fyn-PP2A interactions could contribute to the pathological accumulation of phosphorylated tau proteins, which has been shown in many studies to enhance NMDAR-dependent Ca 2+ influx and promote glutamate excitotoxicity.
impair its nucleic acid safeguarding function and potentiate DNA and RNA oxidative damage in AD brain, and this could be mediated in part by the loss of PP2A/Ba enzymes and PP2A dysfunction in AD [28] .
Ribosomal function of tau
Tau was recently shown to associate with ribosomes [65] . This association is enhanced in AD brain extracts, as evidenced by the detection of tau phosphorylated at Ser396/Ser404 in ribosomal fractions; increased ribosome-tau interactions decrease RNA translation and impair PSD-95 synthesis [65] . These findings suggest that ribosomal tau functions to regulate protein translation, thereby influencing synaptic function, which relies on constant protein synthesis.
Emerging functions of non-neuronal tau
Tauopathies are also characterized by aggregates of tau in glial cells [66] . In oligodendrocytes, tau's interaction with Fyn promotes process outgrowth and could be important for initiating myelination [67] . Tau is also present in platelets from peripheral blood in cognitively normal subjects, and exists in high molecular weight or oligomeric forms in AD platelets [68] . Surprisingly, high molecular weight phosphorylated tau species have also been found in low quantities in non-neuronal cells, including several cancer cell lines [69] . Non-neuronal cytoplasmic and nuclear tau share functional features with brain tau such as the capacity to promote tubulin polymerization, and microtubule binding and stabilization [70] . However, they may also exert additional specific functions that remain to be uncovered.
Significance of PP2A-dependent tau phosphorylation under altered physiological conditions
Many changes to physiologically relevant metabolic processes deregulate PP2A, resulting in increased tau phosphorylation in various animal models. For instance, several studies have linked alterations in glucose metabolism, such as those found in diabetes and hypothermia, to increased tau phosphorylation [71] [72] [73] [74] . Hypothermia is also associated with anesthesia, and increased tau phosphorylation is observed in mice sedated with anesthetic compounds (Reviewed in Ref. [75] ). Notably, low temperatures exponentially decrease the activity of brain-extracted PP2A, while the activities of tau kinases are linearly reduced [72] . On the other hand, increased tau phosphorylation is also apparent in mice sedated under normothermic conditions [76, 77] , probably as a result of deregulation of tau kinases [77, 78] . Such mechanisms could be relevant to public health since anesthesia is widely used and can be associated with postoperative cognitive dysfunction; repeated exposure may even increase AD risk [77] . Brain tau phosphorylation is also increased in a reversible way in hibernating animals [79] . Increased phosphorylated tau levels coincide with downregulation of brain PP2A methylation and activity in hibernating Arctic ground squirrels [80] . In hibernating golden hamsters, soluble hyperphosphorylated tau is associated with spine regression of hippocampal apical dendrites, but does not lead to memory impairment [81] . In this context, the physiological purpose of increased tau phosphorylation, especially at the ADlike PHF-1 epitope, remains unclear. It could represent a neuroprotective mechanism to circumvent NMDAmediated hyperexcitation in response to gradual cooling of the brain during hibernation [79] .
Other metabolic alterations such as hyperhomocysteinemia and low folate/vitamin B 12 status disturb the brain methylation potential and are independent risk factors for sporadic AD and cognitive decline in human populations. Notably, they lead to the downregulation of PP2A methylation and increased tau phosphorylation in vivo (Reviewed in Ref. [10] ).
The accumulation of hyperphosphorylated tau proteins has also been described following traumatic brain injury, and is a substantial risk factor for neurodegeneration [82] .
Lastly, there is increasing evidence for a contribution of stress pathways in enhancement of tau phosphorylation. It is well established that mental stress has a priming role in the development of various psychopathologies (Reviewed in Ref. [83] ), and may even increase the risk for tauopathies. In support of this, the major stress hormones, glucocorticoids, can induce GSK3-mediated tau phosphorylation at Ser-396 in the hippocampus, leading to the impairment of synaptic function; this involves activation of synapse weakening pathways that facilitate LTD [84] . To add to this mechanism, reduced levels of synaptic scaffolding proteins and dendritic spine loss are triggered by glucocorticoids in hippocampal neurons [85] ; those are especially vulnerable to stress due to high expression of glucocorticoid receptors [83] . As mentioned earlier, the pSer-396 tau phosphosite is dephosphorylated by PP2A in vivo, and PP2A also regulates GSK3 activity. Thus, an imbalance between GSK3 and PP2A activities could result in enhanced susceptibility of neurons to stress, and in turn, facilitate phospho-tau-mediated development of neurodegenerative processes.
Significance of altered tau phosphorylation in tauopathies
Disease-associated tau mutations
Frontotemporal dementia with parkinsonism-17-associated mutations of tau not only impede its binding to PP2A but also to microtubules, reducing its ability to promote MT assembly [86] . It is noteworthy that FTDP-17 patients have increased 4R-tau expression. Disease-related tau phosphorylation and missense mutations increase the interaction of 4-repeat tau (4R-tau) and Fyn [87] , while decreasing its binding to PP2A [34] . Thus, deregulation of PP2A/tau/Fyn interactions likely contributes to promote the accumulation of phosphorylated tau in those tauopathies.
The toxic role of tau 'hyperphosphorylation'
Although the toxicity of abnormally phosphorylated tau has been debated for years, it is generally accepted that enhanced tau phosphorylation, especially at selected sites, precedes and promotes the assembly of tau into toxic aggregates in tauopathies (Reviewed in Ref. [88] ). 'Hyperphosphorylated' tau species accumulate in somatodendritic compartments and instigate neurodegenerative cascades via several mechanisms. For instance, the redistribution of axonal tau to the soma, which alters its functionally strategic axonal distribution, could impair axonal transport by inhibiting tau-sensitive kinesin-1 binding to microtubules [49] . Another mechanism could involve excessive tau-dependent sorting of Fyn to the dendrites augmenting excitotoxic signaling induced by amyloid-b in AD [51] . Hyperphosphorylated tau also sequesters normal tau, leading to its toxic coaggregation and decreased supply of 'physiological' tau [88] , ultimately impairing normal synaptic function.
The phosphorylation state of tau also modulates its proteolytic cleavage [89] . Several studies support a role for caspase-mediated tau cleavage as an early event in AD pathology [89] [90] [91] [92] . Caspase-2-mediated cleavage of tau at Asp314 produces the Dtau314 product, which impairs cognitive and synaptic function [90] . Interestingly, specific PP2A subpopulations can indirectly suppress caspase-2 activity [93] , and inhibition of PP2A by okadaic acid alters tau cleavage during neuronal apoptosis [94] . Moreover, GSK3b, which can be activated by PP2A-mediated Ser9 dephosphorylation [18] , is found upstream of caspase-2 activation [95] . Thus, altered PP2A-tau interactions in AD could affect tau cleavage, leading to accumulation of dysfunctional phosphorylated tau in degenerating AD neurons.
A protective role for tau phosphorylation?
A pivotal discovery supports a novel neuroprotective role of site-specific tau phosphorylation, while challenging the historical perception that enhanced tau phosphorylation is systematically associated with neurotoxicity. In this study, tau phosphorylation at Thr205 by p38c kinase, inhibited amyloid-b-induced neuronal death and excitotoxicity [96] by disrupting postsynaptic PSD-95/tau/Fyn complexes [50] . Another study using phosphomimetic tau mutants support a role for phosphorylation at Thr205 in compromising tau's interaction with PSD-95 [52] . Notably, PP2A/Ba can dephosphorylate this site in vitro [18] , and this dephosphorylation might allow to revert tau to its basal low phosphorylated state, so that it can respond to future 'stresses'. The neuroprotective role of pThr205 tau is proposed to occur at the onset of AD pathogenesis, and progressively become overwhelmed by repeated stresses. PP2A has the potential to significantly influence this physiological mechanism, since PP2A directly associates with, dephosphorylates, and inhibits p38 activity in vitro [97] and in vivo [98] . PP2A dysfunction in AD (Reviewed in Ref.
[10]) could contribute to derail these tau-dependent neuroprotective mechanisms.
So, should we target PP2A to treat tauopathies?
PP2A-centric therapies: promises
Together, the leading tau regulatory role and dysfunction of PP2A in AD provide at first sight a compelling rationale for developing PP2A-centric therapies for tauopathies. Targeting the major tau phosphatase is an attractive strategy to normalize or restore the phosphorylation state of pathological tau species. Ideally, this would require early intervention since site-specific phosphorylation of tau can inhibit PP2A phosphatase activity toward other key sites implicated in AD [35] . Many compounds have already been found to enhance basal PP2A activity by several-most often indirectmechanisms, thereby facilitating tau dephosphorylation (Table 1) . However, as outlined below, there are several obstacles for the clinical use of such compounds.
Current PP2A-targeting compounds
Patients with mild and moderate AD have been recruited to evaluate the clinical response to and efficacy of sodium selenate, an inorganic compound that enhances PP2A activity in vitro, reduces phospho-tau pathology, improves spatial learning and memory, and mitigates motor deficits in tauopathy transgenic mouse models [99, 100] . However, its exact mechanism of action and specificity toward PP2A enzymes has not been formally demonstrated.
There are also efforts to target SET, the redistribution of which is a major mechanism for abnormal cytoplasmic tau phosphorylation in AD [31] . Memantine, an uncompetitive NMDAR antagonist used to symptomatically treat AD, inhibits SET-mediated PP2A inhibition and reverses SET-induced abnormal phosphorylation of tau in PC12 cells [31] . The apolipoprotein E mimetic, COG112, also increases PP2A activity by inhibiting its interaction with SET [101] and reduces the phosphorylation and somatodendritic accumulation of hyperphosphorylated tau in the hippocampus and cerebral cortex of AD mouse models [102] .
The loss of PP2A/Ba holoenzymes in AD-affected brain regions [28] parallels the downregulation of PP2A methylation and LCMT1, which is normally abundantly expressed in neurons throughout the cortex [27] . Significantly, alterations in homocysteine and folate metabolism and associated deficits in brain methylation metabolites have been described in AD; they induce a downregulation of LCMT1 and enhanced tau phosphorylation in vivo (Reviewed in Ref.
[10]). Thus, restoring neuronal methylation potential using dietary methylation donors and/or directly targeting the enzymes that control PP2A methylation (Table 1) could facilitate the assembly of PP2A/Ba holoenzymes and increase PP2A-mediated tau dephosphorylation. Indeed, folate and vitamin B 12 supplementation in aged rats prevents hyperhomocysteinemia-mediated PP2A inhibition, tau hyperphosphorylation, and memory deficits [103] . Folic acid supplementation reduces tau phosphorylation by affecting PP2A methylation in diabetic mice [104] . The coffee-derived compound EHT, which decreased the rate of PP2A demethylation by the methylesterase, PME-1, mitigates tau hyperphosphorylation and cognitive impairtment in SET-expressing rats [105] . However, it remains to be established whether this compound could overcome the loss or metabolic deregulation of LCMT1 in AD.
Various compounds of interest for cancer treatment have also been designated as 'PP2A activators', such as forskolin, a cAMP pathway activator, and FTY720, a sphingosine-1-phosphate receptor agonist [106] . Yet, it is worth mentioning that the underlying activating mechanism of such compounds fails to align with the true definition of an enzyme activator, since they indirectly target PP2A. For instance, forskolin indirectly enhances PP2A activity via activation of cAMP signaling [107, 108] . Like COG112 [97] , FTY720 disrupts PP2A-SET interactions, resulting in 'increased cellular PP2A activity' [106] . Of note, SEW2871, a more selective sphingosine-1-phosphate receptor agonist than FTY720, can enhance PP2A methylation and reduce tau phosphorylation [109] .
Issues with specificity and 'off-target' effects of some of these PP2A regulatory compounds
Interestingly, metformin, a drug used to treat diabetes, can decrease tau phosphorylation in a PP2A-dependent manner (Table 1) , by disrupting the interaction of PP2A C subunit with specific regulatory subunits, which normally promotes its degradation [110] . Yet, follow-up studies have found that, despite inducing tau dephosphorylation, metformin promotes tau aggregation and exacerbates abnormal behavior in tauopathy mouse models [111] . While forskolin 'activates' PP2A [107, 108] , it affects cAMP signaling that orchestrates a number of cellular processes, thus increasing the risk of unwanted side effects. Moreover, it enhances phosphorylation of tau at particular sites in primary hippocampal neurons [108] . Forskolin induces PKA-dependent phosphorylation of tau in vivo, which makes tau a more favorable substrate for the major tau kinase GSK-3b [112] . Pharmaceutically targeting SET to 'disinhibit' PP2A catalytic subunit could also pose significant side effects. For instance, FTY720 was found to potentially increase the risk for malignancies in recipients (For instance, see [113] ), and apolipoprotein E-mimetic peptides downregulate p38 activity [114] .
Protein phosphatase 2A being a family of tailored heterotrimers displaying exquisite substrate specificity, the clinical implication of simplistically randomly 'reactivating' cellular pools of PP2A enzymes should be viewed as a matter of concern rather than a therapeutic opportunity. In considering the comprehensive cellular role of the PP2A family of enzymes, and their broad range of substrates, indiscriminately activating 'PP2A' with potent compounds could be toxic. Furthermore, physiological modulators of PP2A ensure a sophisticated regulation to prevent untimely, and thus, detrimental phosphatase activation prior to holoenzyme biogenesis [115] . For instance, PME-1, targeted by EHT [100] , is known to stabilize a nuclear pool of inactive PP2A enzymes [116] . Mechanistically, it is also not clear how 'PP2A activating compounds' could compensate for the loss of the major tau phosphatase, PP2A/Ba, in AD-affected regions, simply by enhancing the catalytic activity of remaining neuronal PP2A isoforms.
However, development of drugs targeting more selectively PP2A regulatory subunits, or disrupting specific PP2A protein signaling complexes could be promising, especially when the target signaling pathways are deregulated in AD. For instance, orally bioavailable small activators of PP2A termed SMAPs, drive activation-inducing conformational changes in PP2A by binding to the Aa subunit, and inhibit ERK signaling [117] . Similarly, the natural anticancer product withaferin A, which also targets Aa, leads to activation of PP2A and inhibition of AKT signaling [118] .
Still, a major challenge will be the toxicity of longterm use of PP2A/tau-targeting compounds, a must for AD patients due to the extended course of this disorder. As mentioned earlier, phosphorylated tau, like PP2A, is also present in other cell types, which could also be a problem for systemic PP2A/tau-directed strategies.
Conclusions and Perspectives
Like many other cytoskeletal and cellular proteins, tau harbors a multitude of validated and predicted phosphorylation sites. Regulated phosphorylation of tau can significantly modulate its distribution, interaction with cytoskeletal components, and cellular functions. While tau proteins are phosphorylated to a certain degree under physiological conditions, abnormally increased phosphorylation has been extensively used as a direct measure or readout of tau toxicity and disease progression in numerous tauopathy studies. Consequently, decreasing overall tau phosphorylation, for instance by inhibiting major tau kinases, has been proposed as a valid approach to counteract tau toxicity in these disorders. Taking into consideration that PP2A enzymes dephosphorylate a majority of tau phosphosites in vivo, control the activity of tau kinases, and are significantly downregulated in AD-affected brain regions, there is increasing interest in developing PP2A-activating compounds to counteract tau pathology. There is a strong rationale for this approach since the deregulation and loss of tau-dedicated PP2A/Ba holoenzymes can directly contribute to deregulation of tau in various experimental models, and likely plays a role in the pathogenic processes underlying tauopathies.
Yet, we argue that the approach of simply activating PP2A-dependent tau dephosphorylation is likely flawed. While a blanket activation of PP2A can induce tau dephosphorylation, PP2A enzymes exert widespread functions. Restoring normal tau function will more specifically require to re-establish normal PP2A/Ba-tau and kinase/tau protein-protein interactions. Those interactions, which critically regulate tau distribution and support tau function as a signaling scaffold, become altered in tauopathies. Therapeutic strategies also need to take into account that correcting common age-and genetic-related metabolic deficits that deregulate PP2A (Reviewed in Ref.
[10]) is essential for restoring neuronal homeostasis. Furthermore, there is increasing evidence that site-specific phosphorylation differentially modulates tau function and toxicity. Indeed, tau phosphorylation at particular sites is important for axonal transport, signaling and neuroprotection. Thus, a better understanding of the role of phosphorylation/ dephosphorylation processes in the regulation and cellular functions of tau is paramount on the challenging and tangled path to development of effective drugs for tauopathies.
